66eP Hunting for blood-based biomarkers for immunotherapy optimization in lung cancer
In the battle against the world’s deadliest cancer, lung cancer, immuno-oncology (IO) treatments have increased the survival of many patients. However, treatment resistance remains the most common outcome. This study aims to address this issue by examining the peripheral immune response in Non-Small Cell Lung Cancer (NSCLC) patients undergoing IO treatment.
Authors
- Z. Darroch
- H.M. Haikala
- M. Gojkovic
- E. Bracalenti
- T.L. Lin
- N. Moradi
- H.K. Laitinen
- J. Smolander
- I. Ilonen
- B. Alsaed
Institutions
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101149
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medicinska Understödsföreningen Liv och Hälsa
- Suomen Kulttuurirahasto
- Tampereen Tuberkuloosisäätiö
- Syöpäsäätiö
- Business Finland